# Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

> **NCT02591290** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 60 (actual)

## Conditions studied

- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate

## Key facts

- **NCT ID:** NCT02591290
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-20
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-03-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591290, "Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02591290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*